advertisement

Diabetes

Updated 01 February 2017

Diabetes weakens your bones

The inflammatory molecule TNF-á may contribute to delayed bone fracture healing in diabetics, new research shows.

0

The inflammatory molecule TNF-á may contribute to delayed bone fracture healing in diabetics, new research shows.

The related report by Alblowi et al, "High Levels of TNF-á Contribute to Accelerated Loss of Cartilage in Diabetic Fracture Healing" appears in the October 2009 issue of the American Journal of Pathology.

Diabetes, a condition where the body either does not produce enough, or respond to, insulin, affects at least 171 million people worldwide, a figure that is likely to double by 2030. Long-term complications of diabetes include cardiovascular disease, chronic renal failure, retinal damage that may lead to blindness, nerve damage, and blood vessel damage, which may cause erectile dysfunction and poor wound healing.

Diabetic patients often experience low bone density, which is associated with increased risk of bone fractures and delayed fracture repair.

Bone repair in mice studied
To examine how diabetes affects bone, Dr Dana Graves and colleagues of the University of Medicine and Dentistry of New Jersey and the Boston University School of Medicine explored bone repair in a mouse model of diabetes. They observed during fracture, increased levels of inflammatory molecules, including TNF-á healing.

The diabetic animals had rapid loss of cartilage in the healing bones, which was due to increased numbers of osteoclasts, cells that remove bone and cartilage. Factors that stimulate osteoclast formation were regulated by both TNF-á and a downstream mediator, FOXO1.

These results suggest that diabetes-mediated increases in TNF-á and FOXO1 may underlie the impaired healing of diabetic fractures.

Alblowi et al suggest that "TNF-á dysregulation plays a prominent role in the recently identified catabolic events associated with diabetic fracture healing."

In future studies, Dr Graves and colleagues plan to "examine the effect of FOXO1 on mineralised tissue to examine how it may regulate factors that control bone resorption and osteoclastogenesis, in addition to effects it may have on osteoblastic cells."

(HealthDay News, September 2009)

Read more: Osteoporosis Centre

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Diabetes expert

Dr. May currently works as a fulltime endocrinologist and has been in private practice since 2004. He has a variety of interests, predominantly obesity and diabetes, but also sees patients with osteoporosis, thyroid disorders, men's health disorders, pituitary and adrenal disorders, polycystic ovaries, and disorders of growth. He is a leading member of several obesity and diabetes societies and runs a trial centre for new drugs.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules